Photocure ASA Reports Impressive Q3 2025 Results with Strong Revenue Growth

Financial Highlights of Photocure ASA for Q3 2025

Photocure ASA, the leading provider of bladder cancer diagnostic solutions based in Oslo, Norway, has issued its financial report for the third quarter of 2025. Their innovative products, Hexvix® and Cysview®, have propelled the company to a revenue milestone of NOK 134.1 million for Q3 2025, reflecting a notable increase from NOK 120.1 million during the same period in 2024. The positive trend in revenues is accompanied by an EBITDA of NOK 10.2 million, a significant leap from the NOK 5.0 million recorded in Q3 2024.

Strategic Growth and Future Outlook

Dan Schneider, the President and Chief Executive Officer of Photocure, expressed his satisfaction with the company’s performance, noting that this quarter continues a strong trajectory of double-digit revenue growth, coupled with positive EBITDA. Schneider remarked, "We maintained our disciplined execution while also advancing new initiatives to enhance our role in precision diagnostics for bladder cancer."

Looking ahead, Photocure is optimistic about continued revenue growth, projecting an 8% to 10% increase on a constant currency basis. This optimistic outlook is slightly adjusted from previous guidance of 7% to 11%. The management anticipates operational leverage flow-through for the core commercial business, anticipating significant growth opportunities in the near future.

Expanding Blue Light Cystoscopy (BLC) Usage

In an effort to bolster its market presence, Photocure has been proactive in deploying new blue light cystoscopy (BLC®) systems. In the third quarter, the company successfully installed 14 new Saphira towers in the United States, gaining seven new accounts along with seven upgrades to existing systems. This indicates a robust growth strategy as the total number of active accounts in the U.S. reached 373, which marks a 23% increase compared to the previous quarter.

Additionally, ForTec has ramped up its acquisition and deployment of BLC towers, contributing to a total of 24 mobile units now in operation due to heightened demand. This growth in mobile BLC technology supports expanding options for healthcare providers and enhances patient care.

Across Europe, Photocure has installed a total of 49 Olympus Visera Elite III systems capable of performing blue light cystoscopy since the system's launch in early 2025.

Strategic Partnership for AI Development

In a landmark move, Photocure announced a partnership with Intelligent Scopes Corporation (ISC), a U.S. subsidiary of Claritas HealthTech. Together, they aim to develop AI software designed to assist physicians during BLC procedures, aiming to improve the detection and management of early-stage bladder cancer significantly.

The agreement entails that Photocure will have exclusive commercialization rights for the AI solution upon regulatory clearance, a pivotal strategy that positions the company as a leader in the ever-evolving landscape of bladder cancer diagnostics.

Future Growth Initiatives

Schneider also highlighted several future initiatives that could further enhance growth trajectories. These include potential CMS reimbursement developments, and the reintroduction of flexible BLC solutions. Additionally, Photocure is optimistic about the entrance of new equipment manufacturers and a potential FDA reclassification favoring BLC technology.

The company is also looking forward to a significant milestone payment from its license agreement with Asieris for Cevira upon regulatory approval in China, marking another potential growth point.

In conclusion, Photocure ASA is on an upward trajectory toward sustained revenue growth, driven by the increasing adoption of their advanced diagnostic technologies and strategic partnerships that align with their mission to improve patient outcomes in bladder cancer.

Conclusion

With its solid financial performance and proactive strategies, Photocure ASA aims to drive more effective diagnostic solutions while reinforcing its position in the medical technology sector. Full financial details can be accessed through their official website, where a presentation is also scheduled to unfold.